PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11056211-0	2000	Inhibition of interleukin-6 signaling by galiellalactone.	galiellalactone	41-56	interleukin 6	Homo sapiens	14-27	
31348843-10	2019	Prostate cancer cells increased the expression of interleukin1beta (IL1beta), IL10, and IL6 in monocytes which was inhibited by galiellalactone.	galiellalactone	128-143	interleukin 6	Homo sapiens	88-91	
30254184-0	2018	The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models.	galiellalactone	20-35	interleukin 6	Homo sapiens	44-47	
30254184-10	2018	Taken together, this finding demonstrates that targeting the IL6/STAT3 pathway with galiellalactone is a viable option to decrease AR activity in prostate tissue that may be applied in a personalized medicine approach.	galiellalactone	84-99	interleukin 6	Homo sapiens	61-64	
11056211-1	2000	A search for inhibitors of the IL-6-mediated signal transduction in HepG2 cells using secreted alkaline phosphatase (SEAP) as reporter gene resulted in the isolation of galiellalactone (1) from fermentations of the ascomycete strain A111-95.	galiellalactone	169-184	interleukin 6	Homo sapiens	31-35	
11056211-2	2000	Galiellalactone inhibits the IL-6-induced SEAP expression with IC(50) values of 250-500 nM by blocking the binding of the activated Stat3 dimers to their DNA binding sites without inhibiting the tyrosine and serine phosphorylation of the Stat3 transcription factor.	galiellalactone	0-15	interleukin 6	Homo sapiens	29-33	
11056211-3	2000	Due to its selective activity, galiellalactone may serve as a lead compound for the development of new therapeutic agents for diseases originating from the inappropriate expression of IL-6 and as molecular tool to dissect the JAK/STAT pathways.	galiellalactone	31-46	interleukin 6	Homo sapiens	184-188